The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study
Open accessAbstract
Background Neurofibrillary pathology has a stereotypical progression in Alzheimer's disease (AD) that is encapsulated in the Braak staging scheme; however, some AD cases are atypical and do not fit into this scheme. We aimed to compare clinical and neuropathological features between typical and atypical AD cases.Methods AD cases with a Braak neurofibrillary tangle stage of more than IV were identified from a brain bank database. By use of thioflavin-S fluorescence microscopy, we assessed the density and the distribution of neurofibrillary tangles in three cortical regions and two hippocampal sectors. These data were used to construct an algorithm to classify AD cases into typical, hippocampal sparing, or limbic predominant. Classified cases were then compared for clinical, demographic, pathological, and genetic characteristics. An independent cohort of AD cases was assessed to validate findings from the initial cohort.Findings 889 cases of AD, 398 men and 491 women with age at death of 37-103 years, were classified with the algorithm as hippocampal sparing (97 cases [11%]), typical (665 [75%]), or limbic predominant (127 [14%]). By comparison with typical AD, neurofibrillary tangle counts per 0.125 mm(2) in hippocampal sparing cases were higher in cortical areas (median 13, IQR 11-16) and lower in the hippocampus (7.5, 5.2-9.5), whereas counts in limbic-predominant cases were lower in cortical areas (4.3, 3.0-5.7) and higher in the hippocampus (27, 22-35). Hippocampal sparing cases had less hippocampal atrophy than did typical and limbic-predominant cases. Patients with hippocampal sparing AD were younger at death (mean 72 years [SD 10]) and a higher proportion of them were men (61 [63%]), whereas those with limbic-predominant AD were older (mean 86 years [SD 6]) and a higher proportion of them were women (87 [69%]). Microtubule-associated protein tau (MAPT) H1H1 genotype was more common in limbic-predominant AD (54 [70%]) than in hippocampal sparing AD (24 [46%]; p=0.011), but did not differ significantly between limbic-predominant and typical AD (204 [59%]; p=0.11). Apolipoprotein E (APOE) ɛ4 allele status differed between AD subtypes only when data were stratified by age at onset. Clinical presentation, age at onset, disease duration, and rate of cognitive decline differed between the AD subtypes. These findings were confirmed in a validation cohort of 113 patients with AD.Interpretation These data support the hypothesis that AD has distinct clinicopathological subtypes. Hippocampal sparing and limbic-predominant AD subtypes might account for about 25% of cases, and hence should be considered when designing clinical, genetic, biomarker, and treatment studies in patients with AD.Funding US National Institutes of Health via Mayo Alzheimer's Disease Research Center, Mayo Clinic Study on Aging, Florida Alzheimer's Disease Research Center, and Einstein Aging Study; and State of Florida Alzheimer's Disease Initiative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“clinical features lack specificity for a pathologic process, but rather indicate brain regions or systems affected by the disease process [3, 4].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three major subtypes of AD can be classified by the relative density of hippocampal neurofibrillary tangles with respect to neocortical tangles [3].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Genetic analyses of APOE suggest APOE4 is more closely linked to typical or limbic predominant than hippocampal sparing AD [3].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Nonamnestic clinical presentations, that is, language, visuospatial, and executive disorders, may also be due to AD [63–66].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [65]
In the citing paper
“Another challenge of CPC studies is that the molecular, anatomic, and clinical changes of AD may not progress in a uniform fashion (7, 12-15).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [12]
In the citing paper
“and that not all AD cases fall within the same spatial continuum with regard to brain NFT distributions (12, 15, 151).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [12]
In the citing paper
“Nevertheless, Braak staging also masks the fact that marked variability in pathologic lesion density across cases exists within a given Braak stage (7, 12)”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationNeurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916
Self-citationAssociation of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., & Hutton, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.711 · Cited by 781
Self-citationBarker, W., Luis, C. A., Kashuba, A., Luis, M., Harwood, D. G., Loewenstein, D., Waters, C., Jimison, P., Shepherd, E., Sevush, S., et al. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200210000-00001 · Cited by 714
Self-citation
Cited by
Sorted by citations
Items 401–500 of 971
Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases
de Ruyter, F. J. H., Evers, M. J. A. P., Morrema, T. H. J., Dijkstra, A. A., den Haan, J., Twisk, J. W. R., de Boer, J. F., Scheltens, P., Bouwman, F. H., Verbraak, F. D., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02769-z · Cited by 27
Khan, A. F., & Iturria‐Medina, Y. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03073-w · Cited by 31
Metabolic regional and network changes in Alzheimer's disease subtypes
Herholz, K., Haense, C., Gerhard, A., Jones, M. S., Anton‐Rodriguez, J., Segobin, S. H., Snowden, J. S., Thompson, J. C., & Kobylecki, C. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17718436 · Cited by 27
Inter-Cohort Validation of SuStaIn Model for Alzheimer’s Disease
Archetti, D., Young, A. L., Oxtoby, N. P., Ferreira, D., Mårtensson, G., Westman, E., Alexander, D. C., Frisoni, G. B., & Redolfi, A. (2021) · Frontiers in Big Data · doi:10.3389/fdata.2021.661110 · Cited by 29
Predicting Conversion from MCI to AD Combining Multi-Modality Data and Based on Molecular Subtype
Li, H.-T., Yuan, S.-X., Wu, J.-S., Gu, Y., & Sun, X. (2021) · Brain Sciences · doi:10.3390/brainsci11060674 · Cited by 27
Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology
Gouilly, D., Rafiq, M., Nogueira, L., Salabert, A., Payoux, P., Péran, P., & Pariente, J. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2022.12.006 · Cited by 31
FDG‐PET markers of heterogeneity and different risk of progression in amnestic MCI
Caminiti, S., Francesco, S. D., Tondo, G., Galli, A., Redolfi, A., & Perani, D. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13385 · Cited by 27
Devi, G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1213968 · Cited by 29
Algarzae, N. K., Hebron, M. L., Miessau, M., & Moussa, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.08.057 · Cited by 29
Maternal genotype influences behavioral development of 3×Tg-AD mouse pups
Blaney, C., Gunn, R. K., Stover, K. R., & Brown, R. E. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.05.033 · Cited by 27
Age-at-Onset and APOE -Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease
Smirnov, D. S., Galasko, D., Hiniker, A., Edland, S. D., & Salmon, D. P. (2021) · Neurology · doi:10.1212/wnl.0000000000011772 · Cited by 25
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
Desikan, R. S., Rafii, M. S., Brewer, J. B., & Hess, C. P. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3644 · Cited by 27
Meyer, V., Holden, M. R., Weismiller, H. A., Eaton, G. R., Eaton, S. S., & Margittai, M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.715557 · Cited by 26
Applications of tau PET imaging
Okamura, N., & Yanai, K. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.38 · Cited by 26
Smirnov, D. S., Salmon, D. P., Galasko, D. R., Goodwill, V., Hansen, L. A., Zhao, Y., Edland, S. D., Léger, G. C., Peavy, G. M., Jacobs, D. M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013107 · Cited by 31
Fujioka, S., Sundal, C., Strongosky, A. J., Castanedes, M. C., Rademakers, R., Ross, O. A., Vilariño‐Güell, C., Farrer, M. J., Wszołek, Z. K., & Dickson, D. W. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1059-4 · Cited by 28
Self-citationPredicting the Rate of Cognitive Decline in Alzheimer Disease
Canevelli, M., Kelaiditi, E., del Campo, N., Bruno, G., Vellas, B. J., & Cesari, M. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000124 · Cited by 26
Sokolovič, L., Hofmann, M., Mohammad, N., & Kukolja, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1267434 · Cited by 33
Cognitively defined Alzheimer's dementia subgroups have distinct atrophy patterns
Crane, P. K., Groot, C., Ossenkoppele, R., Mukherjee, S., Choi, S., Lee, M. K., Scollard, P., Gibbons, L. E., Sanders, R. E., Trittschuh, E. H., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13567 · Cited by 24
Cognitive impairment of workers in a large-scale aluminium factory in China: a cross-sectional study
Meng, H., Wang, S., Guo, J., Zhao, Y., Zhang, S., Zhao, Y., & Niu, Q. L. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027154 · Cited by 28
The temporal lobe in typical and atypical Alzheimer disease
Migliaccio, R., & Cacciamani, F. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-823493-8.00004-3 · Cited by 26
Differential response to donepezil in MRI subtypes of mild cognitive impairment
Diaz‐Galvan, P., Lorenzon, G., Mohanty, R., Mårtensson, G., Cavedo, E., Lista, S., Vergallo, A., Kantarci, K., Hampel, H. J., Dubois, B., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01253-2 · Cited by 25
Hautecloque, G., Sellal, F., Bousiges, O., Phillipi, N., Blanc, F., & Cretin, B. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221197 · Cited by 24
Implication of tau propagation on neurodegeneration in Alzheimer’s disease
Lamontagne-Kam, D., Ulfat, A. K., Hervé, V., Vu, T.-M., & Brouillette, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1219299 · Cited by 28
Devi, G. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98817-9.00015-6 · Cited by 27
Shu, N., Li, X., Ma, C., Zhang, J., Chen, K., Liang, Y., Chen, Y., & Zhang, Z. (2015) · Human Brain Mapping · doi:10.1002/hbm.22954 · Cited by 25
Mez, J., Cosentino, S., Brickman, A. M., Huey, E. D., Manly, J. J., & Mayeux, R. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065246 · Cited by 25
Choi, E.-J., Son, Y., Noh, Y., Lee, H., Kim, Y.-B., & Park, K. H. (2018) · Journal of Clinical Neurology · doi:10.3988/jcn.2018.14.2.158 · Cited by 25
Clinical Correlates of the PET-based Braak Staging Framework in Alzheimer's Disease
Macedo, A. C., Durço, D. F. P. A., Tissot, C., Therriault, J., Vilela de Faria, A. O., Aumont, É., Servaes, S., Rahmouni, N., Fernandez-Arias, J., Wang, Y.-T., et al. (2024) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2024.15 · Cited by 26
Estarellas, M., Oxtoby, N. P., Schott, J. M., Alexander, D. C., & Young, A. L. (2024) · Brain Communications · doi:10.1093/braincomms/fcae219 · Cited by 27
Daniilidou, M., Holleman, J., Hagman, G., Kåreholt, I., Aspö, M., Brinkmalm, A., Zetterberg, H., Blennow, K., Solomon, A., Kivipelto, M., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03072-x · Cited by 27
Bioengineered stem cells in neural development and neurodegeneration research
Yuan, S. H., & Shaner, M. A. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.04.002 · Cited by 24
Can MRI screen for CSF biomarkers in neurodegenerative disease?
McMillan, C. T., Avants, B., Irwin, D. J., Toledo, J. B., Wolk, D. A., Deerlin, V. M. V., Shaw, L. M. J., Trojanoswki, J. Q., & Grossman, M. (2012) · Neurology · doi:10.1212/wnl.0b013e31827b9147 · Cited by 24
SWI and phase imaging reveal intracranial calcifications in the P301L mouse model of human tauopathy
Ni, R., Zarb, Y., Kuhn, G. A., Müller, R., Yundung, Y., Nitsch, R. M., Kulic, L., Keller, A., & Klohs, J. (2020) · Magnetic Resonance Materials in Physics, Biology and Medicine · doi:10.1007/s10334-020-00855-3 · Cited by 24
Frank, B. E., Ally, M., Tripodis, Y., Puzo, C. J., Labriola, C., Hurley, L., Martin, B. M., Palmisano, J. N., Chan, L., Steinberg, E. G., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200304 · Cited by 26
Oatman, S. R., Reddy, J. S., Quicksall, Z., Carrasquillo, M. M., Wang, X., Liu, C., Yamazaki, Y., Nguyen, T., Malphrus, K. G., Heckman, M. G., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00592-2 · Cited by 27
Self-citationRodríguez, J. L., Oltmer, J., Marshall, M., Champion, S. N., Frosch, M. P., & Augustinack, J. C. (2023) · Brain Pathology · doi:10.1111/bpa.13159 · Cited by 22
Pini, L., Geroldi, C., Galluzzi, S., Baruzzi, R., Bertocchi, M., Chitò, E., Orini, S., Romano, M., Cotelli, M., Rosini, S., et al. (2020) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00212-6 · Cited by 26
Quantitative Assessment of Hippocampal Tau Pathology in AD and PART
Zhang, L., Jiang, Y., Zhu, J., Liang, H., He, X., Qian, J., Lin, H. B., Tao, Y., & Zhu, K. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01573-0 · Cited by 24
Memory Resilience in Alzheimer Disease With Primary Progressive Aphasia
Mesulam, M. M., Coventry, C., Kuang, A., Bigio, E. H., Mao, Q., Flanagan, M. E., Gefen, T. D., Sridhar, J., Geula, C., Zhang, H., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011397 · Cited by 23
Modrego, P. J., & Lobo, A. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2019-0006 · Cited by 24
Dulewicz, M., Kulczyńska-Przybik, A., Słowik, A., Borawska, R., & Mroczko, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194575 · Cited by 22
Bouwman, M. M. A., Frigerio, I., Lin, C., Reijner, N., van de Berg, W. D. J., & Jonkman, L. E. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01768-w · Cited by 32
Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach
Rodriguez‐Vieitez, E., & Nordberg, A. K. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_16 · Cited by 24
Brain Networks, Clinical Manifestations, and Neuroimaging of Cognitive Disorders
Bonakdarpour, B., & Takarabe, C. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.07.004 · Cited by 23
He, X., Wu, B., Kuo, K., Zhang, W., Ma, Q., Xiang, S., Li, Y., Wang, Z.-Y., Dong, Q., Feng, J., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01256-z · Cited by 23
Fan, Y., Zhang, Y., Yuan, J., Liu, Z., Zhai, F., Hao, A., Wu, F. Q., Somekh, J., Mor Peleg, B., Zhu, Y., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102247 · Cited by 27
Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer Disease
Kouri, N., Frankenhauser, I., Peng, Z., Labuzan, S. A., Boon, B. D. C., Moloney, C. M., Pottier, C. P., Wickland, D. P., Caetano-Anollés, K., Corriveau‐Lecavalier, N., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.0784 · Cited by 26
Self-citationRoudil, J., and the Brainbank Neuro-CEB Neuropathology Network, Deramecourt, V., Dufournet, B., Dubois, B., Ceccaldi, M. P., Duyckaerts, C. J., Pasquier, F., & Lebouvier, T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170914 · Cited by 23
Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome
Rafii, M. S. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22658 · Cited by 23
A highly predictive signature of cognition and brain atrophy for progression to Alzheimer's dementia
Tam, A., Dansereau, C. L., Iturria‐Medina, Y., Urchs, S. G. W., Orban, P., Sharmarke, H., Breitner, J. C. S., Bellec, P., & Initiative, A. D. N. (2019) · GigaScience · doi:10.1093/gigascience/giz055 · Cited by 22
Garbarino, S., & Lorenzi, M. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117980 · Cited by 27
Differential trajectories of hypometabolism across cognitively-defined Alzheimer’s disease subgroups
Groot, C., Risacher, S. L., Chen, J. Q. A., Dicks, E., Saykin, A. J., Donald, C. L. M., Mez, J. B., Trittschuh, E. H., Mukherjee, S., Barkhof, F., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102725 · Cited by 22
Squitti, R., Catalli, C., Gigante, L., Marianetti, M., Rosari, M., Mariani, S., Bucossi, S., Mastromoro, G., Ventriglia, M., Simonelli, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076377 · Cited by 24
Lerch, O., Ferreira, D., Stomrud, E., van Westen, D., Tideman, P., Palmqvist, S., Mattsson, N., Hort, J., Hansson, O., & Westman, E. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01517-5 · Cited by 24
Cerebrospinal Fluid Biomarkers in Clinical Subtypes of Early-Onset Alzheimer's Disease
Teng, E., Yamasaki, T. R., Tran, M., Hsiao, J. J., Sultzer, D. L., & Mendez, M. F. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000355555 · Cited by 22
Pandya, S., Initiative, A. D. N., Kuceyeski, A. F., & Raj, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160090 · Cited by 24
Taylor, M. E., & Close, J. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63916-5.00019-7 · Cited by 26
Brain perfusion SPECT in dementia: what radiologists should know
Imokawa, T., Yokoyama, K., Takahashi, K., Oyama, J., Tsuchiya, J., Sanjo, N., & Tateishi, U. (2024) · Japanese Journal of Radiology · doi:10.1007/s11604-024-01612-5 · Cited by 21
Neuroimaging in Neurodegenerative Dementias
McGinnis, S. M. (2013) · Seminars in Neurology · doi:10.1055/s-0032-1331808 · Cited by 23
TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy
Zhang, L., Chen, Y., Liu, M., Wang, Y., & Peng, G. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00376 · Cited by 23
Rosa, G., Giannotti, C., Martella, L. A., Massa, F., Serafini, G., Pardini, M., Nobili, F. M., & Monacelli, F. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191075 · Cited by 23
Kuchcinski, G., Patin, L., Lopes, R., Leroy, M., Delbeuck, X., Rollin‐Sillaire, A., Lebouvier, T., Wang, Y., Spincemaille, P., Tourdias, T., et al. (2022) · European Radiology · doi:10.1007/s00330-022-09014-9 · Cited by 21
Alzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 25
Biomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations
Cummings, J. L., & Zhong, K. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.205 · Cited by 21
Alzheimer's disease: mimics and chameleons
Schott, J. M., & Warren, J. D. (2012) · Practical Neurology · doi:10.1136/practneurol-2012-000315 · Cited by 21
Plowey, E. D., & Ziskin, J. L. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0388-2 · Cited by 20
Profiling heterogeneity of Alzheimer's disease using white-matter impairment factors
Sui, X., & Rajapakse, J. C. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.10.026 · Cited by 21
Resting-State Network Alterations Differ between Alzheimer’s Disease Atrophy Subtypes
Rauchmann, B., Ersoezlue, E., Stoecklein, S., Keeser, D., Brosseron, F., Büerger, K., Dechent, P., Dobisch, L., Ertl-Wagner, B. B., Fließbach, K., et al. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhab130 · Cited by 22
Amyloid and tau: neither chicken nor egg but two partners in crime!
Attems, J., & Jellinger, K. A. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1167-9 · Cited by 21
Protective genetic variants against Alzheimer's disease
Mariño, C., Malotaux, V., Giudicessi, A., Aguillon, D. F., Falla, D. S., Lopera, F. J., & Quiroz, Y. T. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00116-4 · Cited by 22
Volumetric MRI Demonstrates Atrophy of the Olfactory Cortex in AD
Alotaibi, M. M., Lessard‐Beaudoin, M., Castellano, C., Gris, D., Cunnane, S. C., & Graham, R. K. (2021) · Current Alzheimer Research · doi:10.2174/1567205017666201215120909 · Cited by 21
Pillai, J. A., Khrestian, M., Bena, J., Leverenz, J. B., & Bekris, L. M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.676744 · Cited by 21
APOE ε4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease
Singh, N. A., Tosakulwong, N., Graff‐Radford, J., Machulda, M. M., Pham, N. T. T., Sintini, I., Weigand, S. D., Schwarz, C. G., Senjem, M. L., Carrasquillo, M. M., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12711 · Cited by 21
Visually Identified Tau 18 F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease
Krishnadas, N., Huang, K., Schultz, S. A., Doré, V., Bourgeat, P., Goh, A., Lamb, F., Bozinovski, S., Burnham, S. C., Robertson, J. S., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215558 · Cited by 20
Knopman, D. S., Jack, C. R., Lundt, E. S., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.2323 · Cited by 20
Self-citationThe olfactory system in Alzheimer’s disease: Pathology, pathophysiology and pathway for therapy
Kovács, T. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0108-3 · Cited by 20
Functional Connectivity of the Hippocampus in Early- and vs. Late-Onset Alzheimer's Disease
Park, K. H., Noh, Y., Choi, E.-J., Kim, H., Chun, S., & Son, Y. (2017) · Journal of Clinical Neurology · doi:10.3988/jcn.2017.13.4.387 · Cited by 20
Prominent Non-Memory Deficits in Alzheimer’s Disease Are Associated with Faster Disease Progression
Scheltens, N. M. E., Tijms, B. M., Heymans, M. W., Rabinovici, G. D., Cohn‐Sheehy, B. I., Miller, B. L., Kramer, J. H., Wolfsgruber, S., Wagner, M., Kornhuber, J., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171088 · Cited by 20
Neurodegenerative Diseases and Ageing
Walker, L., McAleese, K. E., Erskine, D., & Attems, J. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_4 · Cited by 21
Prawiroharjo, P., Yamashita, K., Yamashita, K., Togao, O., Hiwatashi, A., Yamasaki, R., & Kira, J. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04516 · Cited by 20
Posterior Cingulate Cortex Hypometabolism in Non-Amnestic Variants of Alzheimer’s Disease
Bergeron, D., Beauregard, J., Jean-Guimond, Soucy, J., Verret, L., Poulin, S. P., Matías‐Guiu, J. A., Cabrera‐Martín, M. N., Bouchard, R. W., & Laforce, R. J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200567 · Cited by 20
Hromádková, L., Siddiqi, M. K., Liu, H., & Safar, J. (2022) · Cells · doi:10.3390/cells11192997 · Cited by 19
Schork, N. J., Elman, J. A., & Initiative, A. D. N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230548 · Cited by 23
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 18
Neurodiagnostic and neurotherapeutic potential of graphene nanomaterials
Yang, S., Baeg, E., Kim, K., Kim, D., Xu, D., Ahn, J., & Yang, S. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115906 · Cited by 20
Genetic Insights into Alzheimer's Disease
Latimer, C. S., Lucot, K. L., Keene, C. D., Cholerton, B., & Montine, T. J. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032551 · Cited by 20
Indication of retrograde tau spreading along Braak stages and functional connectivity pathways
Seemiller, J., Bischof, G. N., Hoenig, M. C., Tahmasian, M., van Eimeren, T., Drzezga, A. E., & Initiative, A. T. A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05183-1 · Cited by 20
Lee, H. J., Lee, E.-C., Seo, S., Ko, K., Kang, J. M., Kim, W., Seo, H., Lee, S.-Y., Lee, Y., Park, K. H., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.615467 · Cited by 19
MRI-based automated diagnosis of Alzheimer’s disease using Alzh-Net deep learning model
Venkat, S., Ghodeswar, T., Chavan, P., Narayanasamy, S. K., & Srinivasan, K. (2024) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2024.107367 · Cited by 18
Richardson, T. E., Walker, J. M., Farrell, K. W., Oliveira, T. G., White, C. L., & Crary, J. F. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02943-x · Cited by 25
Distinct fiber-specific white matter reductions pattern in early- and late-onset Alzheimer’s disease
Luo, X., Wang, S., Jiaerken, Y., Li, K., Zeng, Q., Hong, H., Guan⁴, X., Guo, T., Wang, C., Zhang, R., et al. (2021) · Aging · doi:10.18632/aging.202702 · Cited by 19
Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
Toledo, J. B., Liu, H., Grothe, M. J., Rashid, T., Launer, L. J., Shaw, L. M. J., Snoussi, H., Heckbert, S. R., Weiner, M. W., Trojanwoski, J. Q., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12305 · Cited by 19
Subtyping Brain Diseases from Imaging Data
Wen, J., Varol, E., Yang, Z., Hwang, G., Dwyer, D., Kazerooni, A. F., Lalousis, P. A., & Davatzikos, C. A. (2023) · Neuromethods · doi:10.1007/978-1-0716-3195-9_16 · Cited by 19
Towards cascading genetic risk in Alzheimer’s disease
Altmann, A., Aksman, L. M., Oxtoby, N. P., Young, A. L., ADNI, Weiner, M., Aisen, P., Petersen, R., Weiner, M., Aisen, P., et al. (2024) · Brain · doi:10.1093/brain/awae176 · Cited by 18
Self-citationHamasaki, H., Honda, H., Suzuki, S. O., Shijo, M., Ohara, T., Hatabe, Y., Okamoto, T., Ninomiya, T., & Iwaki, T. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.04.008 · Cited by 18
Giraldo, D. L., García‐Arteaga, J. D., Cárdenas‐Robledo, S., & Romero, E. (2018) · Brain and Behavior · doi:10.1002/brb3.942 · Cited by 17
Amyloid PET predicts longitudinal functional and cognitive trajectories in a heterogeneous cohort
Younes, K., Johns, E., Young, C. B., Kennedy, G., Mukherjee, S., Vossler, H. A., Winer, J. R., Cody, K. A., Henderson, V. W., Poston, K. L., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70075 · Cited by 18
Self-citationBasanta-Torres, S., Rivas‐Fernández, M. Á., & Galdo‐Álvarez, S. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111028 · Cited by 19
Molecular features of human pathological tau distinguish tauopathy-associated dementias
Kumar, M., Schlaffner, C. N., Tang, S., Beuvink, M. A., Viodé, A., Mair, W., Jha, M., Uncu, C., Wesseling, H., Wang, T., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.036 · Cited by 21
Self-citation
Metadata
- Authors
- Murray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. W.
- Affiliations
- Mayo Clinic (US)
- Mount Sinai Medical Center (US)
- Corresponding author
- Dickson, Dennis W
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 10
- Issue
- 9
- Pages
- 785-796
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC3175379
- OpenAlex
- W2075444764
- Cited by
- 972
- References
- 44
- Citations by year
- 2026: 60 · 2025: 80 · 2024: 78 · 2023: 96 · 2022: 80 · 2021: 104 · 2020: 70 · 2019: 73 · 2018: 56 · 2017: 50 · 2016: 55 · 2015: 37 · 2014: 36 · 2013: 54 · 2012: 35
- FWCI
- 29.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Mayo Clinic
- National Institutes of Health
- National Institute on Aging (P50‐AG16574, U01AG06786, P50 AG215711, P01AG03949, U01AG006786, P01AG003949, R21AG038736, P50AG025711, P01AG017216, P50AG016574)
- National Institute of Neurological Disorders and Stroke (P50NS072187)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary tangles, Braak staging, hippocampal sparing, hippocampal atrophy, tau pathology, clinical features, atypical Alzheimer's disease, sex differences, age at death, genetic risk factors
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Hippocampus, Humans, Limbic System, Male, Middle Aged, Retrospective Studies, Cohort Studies, Neurofibrillary Tangles, tau Proteins, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
